Pilot Study : FreeStyle Libre Pro Flash Continuous Glucose Monitoring System in Subjects With Diabetes on HemoDIALsis (FSL DIAL)
FreeStyle Libre Pro Flash Continuous Glucose Monitoring (CGM) System in Subjects With Diabetes on HemoDIALsis (FSL-DIAL Pilot Study)
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Fanny Doroszewski
- Phone Number: 00330478618398
- Email: fdoroszewski@chsjsl.fr
Study Locations
-
-
-
Lyon, France, 69365
- Centre Hospitalier Saint Joseph Saint Luc
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Diabetes without any change in treatment in the last 3 months
- Hemodialysis for > 3 months
- Recent laboratory HbA1c (< 15 days)
Exclusion Criteria:
- Patient does not show non-opposition
- Skin allergy to the sensor
- Sepsis / Acute anaemia
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Difference between estimated Hba1c (or Glucose Management Index (GMI)) with FreeStyle Libre Pro sensor and laboratory Hba1c
Time Frame: At sensor removal (day 14)
|
Comparison between estimated HbA1c with 14 days of CGM data and laboratory HbA1c (routine blood test in hemodialysis) in each subject
|
At sensor removal (day 14)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time in glucose range
Time Frame: At sensor removal (day 14)
|
Percent (%) time in glucose range of ≥70 to ≤180 mg/dL (≥3.9 to ≤10 mmol/L), obtained using professional continuous glucose monitoring (CGM)
|
At sensor removal (day 14)
|
|
Time with Glucose < 70mg/dL
Time Frame: At sensor removal (day 14)
|
% time with glucose <70 mg/dL
|
At sensor removal (day 14)
|
|
Time with Glucose > 180 mg/dL
Time Frame: At sensor removal (day 14)
|
% time with glucose >180 mg/dL
|
At sensor removal (day 14)
|
|
Glucose total coefficient of variation (CV)
Time Frame: At sensor removal (day 14)
|
Glucose total CV (%)
|
At sensor removal (day 14)
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Lucien Marchand, MD, study principal investigator
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- FSL DIAL
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.